These findings indicate that HDAC2 up-regulation protected CML cells resistant to IM from cell cycle arrest in the G2/M phase induced by the combined treatment. The gene discussed is HDAC2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.